In recent years, immune checkpoint inhibitors (ICIs) targeting the programmed death ligand‐1 (PD‐L1)/PD‐1 immune checkpoint axis have shown promising results in the treatment of NSCLC, including LUSC [4]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.